Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tremelimumab Clear all
Recruiting Phase 2 Interventional

IIT2025-03-YANG-LIFT-HCC

NCT07489976
View directory record Official record
Conditions
Hepato Cellular Carcinoma
Interventions
STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)
Drug
Lead sponsor
Ju Dong Yang
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

NCT02535078
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Tebentafusp (IMCgp100)
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Phase 1 Interventional

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

NCT06710223
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SD-101, Cryotherapy, Tremelimumab, Durvalumab
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

NCT03557918
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Tremelimumab
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Early Phase 1 Interventional

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

NCT02812420
View directory record Official record
Conditions
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Interventions
Durvalumab, Therapeutic Conventional Surgery, Tremelimumab
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

NCT05027425
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
Interventions
Durvalumab, Tremelimumab, Liver Transplant
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NCT03164772
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer, NSCLC
Interventions
Durvalumab, Tremelimumab, BI 1361849, PharmaJet Tropis® device
Drug · Biological · Device
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Gilbert, Arizona • Tampa, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

NCT03116529
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Combination Radiation, Immunotherapy, Surgery
Combination Product
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Phase 2 Interventional

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

NCT04395079
View directory record Official record
Conditions
Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm
Interventions
Durvalumab, Internal Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

NCT02536794
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Anti-B7H1 Monoclonal Antibody MEDI4736, Laboratory Biomarker Analysis, Pharmacological Study, Tremelimumab
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

NCT03089645
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI5083 monotherapy, MEID5083 with Durvalumab or Tremelimumab, Medi5083 with Durvalumab and Docetaxel
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Hackensack, New Jersey • Providence, Rhode Island • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

NCT02558894
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
MEDI4736 monotherapy, tremelimumab+MEDI4736
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

NCT02340975
View directory record Official record
Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
MEDI4736 + tremelimumab, MEDI4736, Tremelimumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

NCT00257205
View directory record Official record
Conditions
Melanoma
Interventions
dacarbazine, CP-675,206, temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
55
States / cities
Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927
View directory record Official record
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

NCT03237377
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 1 Interventional

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

NCT02868632
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068
View directory record Official record
Conditions
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Interventions
Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

NCT03144778
View directory record Official record
Conditions
Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

NCT02117219
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
MEDI4736 Evaluate MEDI4736 in MDS, VIDAZA, tremelimumab
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

NCT03581487
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Durvalumab, Selumetinib, Tremelimumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Recruiting Phase 2 Interventional

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

NCT06698250
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Zanzalintinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 1, 2026, 10:42 AM EDT